Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 574 participants.
Also called NCT05554822
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 574 participants
- Registry
-
NCT05554822
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Italy
- Registry status
- Unknown status
Technical summary
Registry record NCT05554822. Randomized; no masking; primary purpose treatment. Start 2021-06-14 (actual); primary completion 2023-12-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study
- Acronym
- ARMYDA-AMULET
- Condition
- Left Atrial Appendage Occlusion
- Condition
- Antiplatelet Therapy
- Intervention (Drug)
- Aspirin 100mg
- Intervention (Drug)
- Aspirin 100 mg OD plus clopidogrel 75 mg OD
- Lead sponsor
- Azienda Ospedaliero Universitaria Maggiore della Carita
- Collaborator
- Abbott Medical Devices
Record details
- Record id
cardio:ct-nct05554822- Content hash
07580171a59f6bf4824fd82f9baea15653920e002e146b8fc54c613229da56c1